Alzheimer’s patients are set to find out whether a new drug could become available in the UK as health regulators are poised to announce their decision on donanemab.
The treatment – one of two new drugs to target a cause of the disease – has been considered by the medicines regulator and the NHS spending watchdog.
A decision is expected imminently.
Donanemab, manufactured by pharmaceutical giant Eli Lilly, is a targeted antibody drug which slows down the early stages of Alzheimer’s.
The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in research because they target a known cause of the disease, rather than just treating the symptoms.
In August, the Medicines and Healthcare products Regulatory Agency said that lecanemab is efficient at slowing Alzheimer’s disease and made it the first drug of its kind to be licensed for use in Great Britain.
But the National Institute for Health and Care Excellence (Nice) said that the drug should not be rolled out for widespread use across the NHS.
The NHS spending watchdog said the benefits of lecanemab are “just too small to justify the significant cost to the NHS”.
One charity said that it is “deeply disappointing” that patients with early stage Alzheimer’s will not have access to the drug on the health service “and it will only be available to those who can pay privately”.
Dementia experts have questioned whether a similar decision could be taken for donanemab.
Both drugs bind to amyloid, a protein which builds up in the brains of people living with Alzheimer’s disease.
By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline.
Evidence suggests that people get the most benefit if they are given the treatment earlier in the disease.
Clinical trials testing the safety and efficacy of donanemab, also known as Kisunla, found that it could slow the rate at which memory and thinking get worse by more than 20%.
Results also suggest the drug leads to a 40% reduction in the decline of everyday activities such as driving, enjoying hobbies and managing money.
The drug, which is given to patients via an intravenous drip once every four weeks, does carry a risk of side effects – some of them serious, including brain swelling and micro brain bleeds.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here